| 3.28 0.2 (6.49%) | 10-08 13:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.89 | 1-year : | 4.54 |
| Resists | First : | 3.33 | Second : | 3.89 |
| Pivot price | 3.06 |
|||
| Supports | First : | 2.55 | Second : | 2.07 |
| MAs | MA(5) : | 3.09 |
MA(20) : | 2.95 |
| MA(100) : | 2.15 |
MA(250) : | 7.69  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 71.9 |
D(3) : | 64.8 |
| RSI | RSI(14): 65.6 |
|||
| 52-week | High : | 19.94 | Low : | 1.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMLX ] has closed below upper band by 3.0%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.18 - 3.2 | 3.2 - 3.21 |
| Low: | 2.99 - 3.01 | 3.01 - 3.03 |
| Close: | 3.04 - 3.08 | 3.08 - 3.11 |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Sun, 06 Oct 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by American Century Companies Inc. - MarketBeat
Fri, 04 Oct 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by AQR Capital Management LLC - MarketBeat
Thu, 03 Oct 2024
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - Morningstar
Tue, 01 Oct 2024
Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility - TipRanks
Mon, 09 Sep 2024
Amylyx Pharmaceuticals: Management Ambitiously Navigates Challenges (NASDAQ:AMLX) - Seeking Alpha
Mon, 09 Sep 2024
Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 4.643e+007 (%) |
| Held by Institutions | 14.3 (%) |
| Shares Short | 1,970 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7664e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -55.6 % |
| Operating Margin | 7 % |
| Return on Assets (ttm) | 457 % |
| Return on Equity (ttm) | -28.3 % |
| Qtrly Rev. Growth | 2.9876e+008 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.85 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.56 |
| Price to Cash Flow | -0.48 |
| Dividend | 0 |
| Forward Dividend | 1.26e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|